November 21st 2022
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announced that the resumption of commercial implants of its Aeson® artificial heart is now effective
On October 25, CARMAT announced that the DEKRA notified body had approved all the changes implemented on Aeson®, thus allowing the Company to resume commercial implants in the European Union and other countries that recognize CE Marking.
In view of this, a first commercial implant of Aeson® was performed in a German hospital last week. The Company reminds readers that implants will continue to resume at a gradual pace in line with the rebuilding of its inventory of implantable prostheses.
In accordance with the principles it has consistently applied, the Company does not plan to communicate on the state of health of individual patients nor on the performance of each implantation. CARMAT will continue to communicate on its progress when it reaches significant milestones and when it publishes its financial results.